Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Wang-Soo | - |
dc.contributor.author | Kim, Jaetaek | - |
dc.date.available | 2019-03-07T04:36:46Z | - |
dc.date.issued | 2018-07 | - |
dc.identifier.issn | 1738-642X | - |
dc.identifier.issn | 2092-8467 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1994 | - |
dc.description.abstract | Purpose of review: Tyrosine kinase inhibitors (TKIs) have shown clear survival benefits as effective targeted therapies in various hematological and solid malignancies. Important evidence, however, has shown that TKIs may lead to adverse effects such as cardiovascular toxicities, via off-target as well as on-target mechanisms. This review presents an overview of TKI-induced cardiotoxicity mechanisms, clinical manifestations, diagnosis, monitoring, and management options. Furthermore, we discuss current preclinical efforts and future investigations into alternative therapeutics for minimizing the cardiotoxicities associated with tyrosine kinase-targeted therapies. Recent findings: Accompanying with the significant improvements toward targeted anticancer treatment, cardiotoxicity-related adverse effects are increasingly reported and have become an important public health issue. The TKI-induced cardiovascular toxicities include myocardial ischemia, heart failure, QT prolongation, and hypertension. Thus, the early awareness of cardiotoxicities, initiation of appropriate management, and close follow-up, may enhance the benefits of TKI therapy. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN SOCIETY TOXICOGENOMICS & TOXICOPROTEOMICS-KSTT | - |
dc.title | Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s13273-018-0027-z | - |
dc.identifier.bibliographicCitation | MOLECULAR & CELLULAR TOXICOLOGY, v.14, no.3, pp 247 - 254 | - |
dc.identifier.kciid | ART002362395 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000436131600001 | - |
dc.identifier.scopusid | 2-s2.0-85060344121 | - |
dc.citation.endPage | 254 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 247 | - |
dc.citation.title | MOLECULAR & CELLULAR TOXICOLOGY | - |
dc.citation.volume | 14 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Neoplasm | - |
dc.subject.keywordAuthor | Drug therapy | - |
dc.subject.keywordAuthor | Cardiotoxicity | - |
dc.subject.keywordAuthor | Heart failure | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | RENAL-CELL CARCINOMA | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordPlus | CANCER-THERAPIES | - |
dc.subject.keywordPlus | CARDIOVASCULAR TOXICITY | - |
dc.subject.keywordPlus | CARDIAC DYSFUNCTION | - |
dc.subject.keywordPlus | INHIBITOR SUNITINIB | - |
dc.subject.keywordPlus | ADJUVANT THERAPY | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Toxicology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Toxicology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.